startric
Seriously driven
by innovation.
Founded to deliver a breakthrough solution for TR patients, StarTric has brought together clinical innovators, creative developers, entrepreneurial executives and world-class advisors aligned on a single therapeutic goal.
startric
Seriously driven by innovation.
Founded to deliver a breakthrough solution for TR patients, StarTric has brought together clinical innovators, creative developers, entrepreneurial executives and world-class advisors aligned on a single therapeutic goal.
our vision
For more patients, for longer lives.
StarTric’s vision is to redefine the standard of care for tricuspid regurgitation through TriClover™: the only next generation TEER clover system. We want to expand TR treatment to more patients, including those with limited or no options.
Our project is grounded in the intuition that, as per the mitral valve, a proven surgical edge-to-edge technique can be translated into an effective percutaneous approach.
“Today, we have the opportunity to replicate a surgical technique of our own invention using transcatheter technology. The theoretical foundations are strong, and we must continue to insist on them. At this moment, we are operating in the absence of highly effective transcatheter alternatives.”
Prof. Ottavio Alfieri
Leadership Team
Daniele Zanotti
CEO
A global medtech CEO with academic engineering background, an MBA from INSEAD and 30+ years taking diverse medical technologies from concept to clinic. At StarTric to scale up TriClover.
Eugenio Passanante
Co-founder · CFO & COO
Serial U40 entrepreneur, leading a high-tech medical and cardiovascular distribution business. Founded StarTric to carry forward a family project, making a proven technique accessible to more TR patients.
Francesco Napolitano
Co-founder · President
Twenty-five years of executive leadership across medical device corporations, evolving into a founder and CEO, active across multiple healthcare markets. Brings to StarTric board-level, commercial and operational experience.
Marco Gard
CTO
Medtech R&D expert and entrepreneur, holder of several medtech patents, guiding cardiovascular technologies from design through industrialization, into clinical use. At StarTric to translate the clover into a successful transcatheter device.
Marianna Luppi
CRQO
Steering regulatory strategy for innovative medtech technologies for 20 years, securing product approvals across nearly every global market at large corporations and start-ups. Leads Startric’s regulatory and quality strategy.
Laura Monti
Head of communications
Shaping global healthcare and medtech communications programs, launching new products and sustaining start-up valuations. At StarTric to drive the narrative around its roadmap towards patients.
Clinical Team and Advisory Board
Board member
Ottavio Alfieri
Co-founder · clinical Advisor
A defining figure in cardiac surgery evolution. Among his crucial contributions, the mitral and tricuspid edge-to-edge repair techniques: the Alfieri-stitch and the Clover. Established the Alfieri Foundation for the Heart. At StarTric to see the clover benefit millions of TR patients.
Board member
Azeem Latib
Clinical Advisor
Director of structural heart interventions at Montefiore-Einstein (NY-USA), a key voice at most interventional cardiology congresses and a global opinion leader for the advancement of new technologies. Advising StarTric on system concept and clinical validation.
Board member
Michele De Bonis
Co-founder · CMO
Associate Professor and Head of cardiac surgery at San Raffaele Hospital (Milan-I), ESC EACTS Guidelines on Valvular Heart Disease task force member. Co-developed and performed the surgical clover since its conception. Co-founded StarTric to lead it into transcatheter intervention.
Board member
Maurizio Taramasso
Clinical Advisor
Cardiac surgeon and interventional cardiologist at the HerzZentrum Hirslanden (Zurich-CH). A globally recognised expert and trusted advisor for the development and validation of innovative interventional devices. Guiding TriClover’s performance and usability.
Board member
Antonios Pitsis
Clinical Advisor
Head of cardiac surgery at European Interbalkan Medical Center (Thessaloniki-GR). Pioneered a totally endoscopic clover with results closely validating TriClover’s concept. At StarTric to support technology development and validation, drawing on his clinical experience.
Antonio Mangieri
Clinical Advisor
Interventional cardiologist at Humanitas Research Hospital (Milan-I), and an experti in advancing transcatheter valvular therapies. His close involvement with StarTric’s R&D on preclinical work and upcoming clinical preparation is shaping TriClover’s implanting procedure.
Francesco Ancona
Clinical Advisor
Echocardiologist at San Raffaele Hospital, (Milan-I) specializing in imaging for percutaneous mitral and tricuspid interventions – an essential element in transcatheter tricuspid treatment. At StarTric to build TriClover’s clinical imaging expertise.
Investors
